Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Affectis Pharmaceuticals AG

www.affectis.com

Latest From Affectis Pharmaceuticals AG

EMBL Ventures Snags $55 Million In First Closing For New European VC Fund

Despite an ongoing European financial crisis, Germany's EMBL Ventures collects $55 million for its next venture fund to invest in European biotech.

BioPharmaceutical Europe

Deals Shaping the Medical Industry (07/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

Merck-Serono licenses 'brain-penetrant' anti-P2X7 programme from Affectis

Merck Serono (Merck KGaA) has signed an exclusive licensing agreement with Affectis Pharmaceuticals of Germany for the development and commercialisation of oral compounds targeting P2X7 receptors. The deal does not include Affectis' lead P2X7 antagonist, AFC-5128, which is in advanced preclinical development, Affectis' CBO Luc St-Onge told Scrip.

Orthopedics Neurology

Recent Financings of Private Companies (04/2010)

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • Neuronova AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Affectis Pharmaceuticals AG
  • Senior Management
  • Manfred Rudiger, CEO
    Luc St-Onge , PhD, CBO
    Michael Bös, PhD, CSO
  • Contact Info
  • Affectis Pharmaceuticals AG
    Phone: (49) 89 893 2811 100
    Fraunhoferstrasse 13
    Martinsried, 82152
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register